ANDA 91624, held by Lannett Co Inc. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 91624 (Atorvastatin Calcium), held by Lannett Co Inc, was first approved by FDA on Apr 5, 2013, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 5, 2013 | Original application | Approved |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Nov 19, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 19, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 5, 2013 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters